To include your compound in the COVID-19 Resource Center, submit it here.

Heron’s HTX-011 meets Phase III postoperative pain endpoints

Heron Therapeutics Inc. (NASDAQ:HRTX) said HTX-011 met the primary and key secondary endpoints in the Phase III EPOCH1 and EPOCH2 trials to treat postoperative pain. The company reiterated its plan

Read the full 302 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE